Objective
to determine whether FFRangio-guided treatment is non-inferior to pressure wire-guided treatment in patients with CCS or NSTE-ACS undergoing angiography with at least one lesion suitable for physiological assessment
Study
prospective, multicentre, randomised, open-label, non-inferiority trial
Population
adults 18 years with CCS or NSTE-ACS, at least one 50-90% angiographic stenosis suitable for PCI and both FFRangio and pressure wire assessment, without prior CABG
Endpoints
composite of death, myocardial infarction, or unplanned, clinically indicated coronary revascularisation at 1 year
Conclusion
FFRangio was found to be noninferior to pressure wire guidance in terms of a composite endpoint of death, myocardial infarction, or unplanned coronary revascularisation at 1 year.
Fearon et al. N Engl J Med. 2026 Mar 29.